IDRA Share Price

Open 2.37 Change Price %
High 2.41 1 Day -0.01 -0.42
Low 2.32 1 Week -0.28 -10.49
Close 2.39 1 Month 0.17 7.66
Volume 567817 1 Year 0.49 25.79
52 Week High 2.87
52 Week Low 1.30
IDRA Important Levels
Resistance 2 2.47
Resistance 1 2.44
Pivot 2.37
Support 1 2.34
Support 2 2.31
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
DCTH 0.04 33.33%
RITT 0.04 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NEXS 0.05 25.00%
PRAN 3.25 24.52%
PGRX 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
LIWA 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

IDRA Technical Analysis 3
As on 19th Oct 2017 IDRA Share Price closed @ 2.39 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.88 & Buy for SHORT-TERM with Stoploss of 2.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDRA Target for October
1st Target up-side 2.54
2nd Target up-side 2.76
3rd Target up-side 2.98
1st Target down-side 1.92
2nd Target down-side 1.7
3rd Target down-side 1.48
IDRA Other Details
Segment EQ
Market Capital 20456252.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.iderapharma.com
IDRA Address
IDRA
167 Sidney Street
Cambridge, MA 02139
United States
Phone: 617-679-5500
Fax: 617-679-5592
IDRA Latest News
Interactive Technical Analysis Chart Idera Pharmaceuticals, Inc. ( IDRA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Idera Pharmaceuticals, Inc.
IDRA Business Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.